A One-Year, Multicenter, Partially Blinded, Double-Dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-Dose or Full-Dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-Dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in De Novo Adult Renal Transplant Recipients.

Trial Profile

A One-Year, Multicenter, Partially Blinded, Double-Dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-Dose or Full-Dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-Dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in De Novo Adult Renal Transplant Recipients.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2011

At a glance

  • Drugs Fingolimod (Primary) ; Ciclosporin; Corticosteroids; Mycophenolate mofetil
  • Indications Renal transplant rejection
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 01 Nov 2011 Actual end date of the extension trial (NCT00239811) is May 2006.
    • 01 Nov 2011 Actual end date of the extension trial (NCT00239811) is May 2006.
    • 01 Nov 2011 Actual initiation date of the extension trial (NCT00239811) is Apr 2004.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top